Supportive Care Strategies for Managing Newly Diagnosed Multiple Myeloma

Please Log In or Register to continue.

Release Date: September 28, 2018
Expiration Date: September 28, 2019

Expected time to complete this activity as designed: 60 minutes
There are no fees for participating in or receiving credit for this online activity.

Program Overview

The treatment landscape for multiple myeloma (MM) continues to evolve, largely because of improvements in diagnosing the disease and advances in treatment for newly diagnosed patients. Oncology nurses are constantly challenged to stay up-to-date with recent advances in the management of newly diagnosed MM (NDMM).

To appropriately manage NDMM, a full patient workup using guideline-based testing strategies and key laboratory tests is required. Patients must understand the impact of myeloma-defining events on determining when treatment will be started. In addition, nurses are at the forefront of providing supportive care to NDMM patients when new therapies and treatment plans are initiated. They must balance potential benefits with tolerability and risks for side effects.

In this activity, Dr. Philip McCarthy outlines important steps for accurately diagnosing patients with suspected MM, and strategies for using that information to develop effective, individualized treatment regimens. Dr. Kumar discusses important considerations when using novel therapies in NDMM, including comorbidities and treatment-related adverse events. These factors must be appropriately assessed and monitored to optimize safety and prevent premature discontinuation of therapy.

Target Audience

This activity is designed for nurses in the community setting who provide care to patients with multiple myeloma.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Define guideline-based testing strategies for multiple myeloma diagnostic workup
  • Outline disease definitions in asymptomatic and symptomatic multiple myeloma
  • List myeloma-defining events (MDEs) and their impact on determining when to initiate treatment
  • Summarize current risk stratification process and methodologies


The Diagnostic Workup for Multiple Myeloma: Guidelines and Recommendations – Philip L. McCarthy, MD

Novel Therapies for the Treatment of Newly Diagnosed Multiple Myeloma – Shaji K. Kumar, MD

Instructions for Participation and Credit

This activity is eligible for credit through September 28, 2019. After this date, this activity will expire and no further credit will be awarded.

  1. Read the target audience, learning objectives, and faculty disclosures.
  2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
  3. Complete the educational content as designed.
  4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
  5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
  6. Certificates for CNE may be printed immediately after successfully completing the post-test and activity evaluation.

Faculty Biographies

Philip L. McCarthy, MD
Professor of Oncology
Director, Blood and Marrow Transplant Program
Roswell Park Cancer Institute
Buffalo, New York

Dr. Philip McCarthy received his medical degree from Tufts University School of Medicine, Boston, Massachusetts. He completed an internship and residency at Yale-New Haven Hospital, and hematology and medical oncology fellowship training at Brigham and Women's Hospital and Dana Farber Cancer Institute. Dr. McCarthy is Professor of Oncology and Director of the Blood and Marrow Transplant Program at Roswell Park Cancer Institute, Buffalo. He is also Professor of Internal Medicine at the State University of New York at Buffalo.

Dr. McCarthy is a diplomate, American Board of Internal Medicine, with subspecialty certification in medical oncology and hematology, and holds membership in the American Society of Hematology (ASH), American Society for Blood and Marrow Transplantation (ASBMT), American Society of Clinical Oncology (ASCO), American Association of Blood Banking (AABB), and the American Association for Cancer Research (AACR). He is associate chair of the Myeloma Committee of the Alliance for Clinical Trials in Oncology (ACTION) and a member of the Transplant Committee. He is an associate editor of the Biology of Blood and Marrow Transplantation journal, as well as an ad hoc reviewer for several journals including Blood, Bone Marrow Transplantation, Journal of Clinical Oncology, Haematologica, Leukemia and Lymphoma, and JNCCN. Dr. McCarthy has published more than 200 peer-reviewed manuscripts and reviews. His major research interests include blood and marrow transplantation, graft-versus-host disease/graft-versus-tumor effect, cancer immunotherapy, and multiple myeloma.

Shaji K. Kumar, MD
Professor of Medicine
Mayo Clinic College of Medicine
Consultant, Division of Hematology
Medical Director, Cancer Clinical Research Office
Mayo Clinic
Rochester, Minnesota

Dr. Shaji Kumar received his medical degree from All India Institute of Medical Sciences in New Delhi, India. His postdoctoral training included a residency in internal medicine from the All India Institute of Medical Sciences, followed by a residency in internal medicine and a fellowship in hematology/oncology at the Mayo Graduate School of Medicine in Rochester, Minnesota. He is currently the Medical Director for the Cancer Center Clinical Research Office which oversees the development, activation, conduct, and monitoring of interventional trials across the three site Mayo Clinic Cancer Center.

Certified by the American Board of Internal Medicine (ABIM) in internal medicine, medical oncology, and an ABIM diplomate in hematology, Dr. Kumar holds membership in several professional organizations including the American Society of Hematology, American Society of Clinical Oncology, American Association for Cancer Research, American Society of Blood and Marrow Transplantation, the Association of Physicians of India, and the European Hematology Association. He has published numerous articles, abstracts, editorials, and letters in the peer-reviewed literature, including Blood, Journal of Clinical Oncology, Leukemia, American Journal of Hematology, British Journal of Haematology, and Bone Marrow Transplantation. He is also a member of the editorial board for several journals including American Journal of Hematology, European Journal of Clinical and Medical Oncology, and Leukemia.

Dr. Kumar’s research focuses on the development of novel drugs for the treatment of myeloma, and he has presented nationally and internationally. He is the principal investigator of several phase 1 and phase 2 clinical trials exploring new drugs and combinations for newly diagnosed and relapsed myeloma. His laboratory is focused on understanding the role of bone marrow microenvironment in the development and progression of myeloma.


Accreditation Statement: MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 18-037-085


As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosures

Dr. Philip McCarthy has received honoraria as a consultant from Bristol-Myers Squibb Company, Celgene Corporation, Janssen Pharmaceuticals, Inc., Karyopharm Therapeutics, Sanofi, Takeda Oncology, and The Binding Site Ltd. He has received grant support related to research activities from Celgene.

Dr. Shaji Kumar has received honoraria as a consultant from AbbVie Inc., Amgen Inc., Celgene Corporation, Genentech, Inc., Janssen Pharmaceuticals, Inc., Kite Pharma, MedImmune, LLC, Merck & Co., Inc., Oncopeptides AB, and Takeda Oncology. He has received grant support related to research activities from AbbVie, Amgen, Bristol-Myers Squibb Company, Celgene, Janssen, F. Hoffmann-La Roche Ltd, Genentech, Kite, MedImmune, Merck, Novartis AG, Sanofi, and Takeda.

Planning Committee Disclosures

The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Kristin Burke, Project Manager, Keith D’Oria, Medical Writer, and Joan Meyer, RN, MHA, Executive Director, have no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Amgen, Bristol-Myers Squibb, Celgene Corporation, and Takeda Oncology

©2018 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

Please Log In or Register to continue.